Immunicon entered into laboratory service and assay development agreements with Merck Serono. The transactions cover laboratory service testing and development of specialized biomarker assays based on circulating tumor cells, within the scope of an early clinical drug study.
“The ability to interrogate the extremely rare circulating cells once isolated from peripheral blood gives unprecedented opportunities to see in real time what is happening with tumor cells in patients upon exposure to investigational drugs,” says Leon Terstappen, M.D. Ph.D., CSO of Immunicon.
“On top of testing kinetics of circulating tumor cells, which may give important information on drug activity itself, the assays we will be developing in this project may provide predictive information as to who is likely to react to the drug and who is not.”